You are here
Open
NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.
If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).
-
PAR-21-057: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
Release Date: 11-19-2020Open Date: 01-22-2021 Due Dates: Multiple Close Date: 09-08-2023Background A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints, as well as composite biomarkers or biomarker signatures. Becaus ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-MD-23-002: Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)
Release Date: 01-30-2023Open Date: 02-24-2023 Due Dates: Multiple Close Date: 09-07-2023Despite continued improvement in the health of the U.S. population with the introduction of medical and scientific advances, there continues to be an alarming disproportionate burden of illness among certain population groups. The mission of the NIMHD is to lead scientific research aimed at the development of innovative diagnostics, treatments, and prevention strategies to improve minority health ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-MD-23-003: Innovations for Healthy Living- Improving Minority Health and Eliminating Health Disparities (R43/R44- Clinical Trial Optional)
Release Date: 01-30-2023Open Date: 02-24-2023 Due Dates: Multiple Close Date: 09-07-2023Despite continued improvement in the health of the U.S. population with the introduction of medical and scientific advances, there continues to be an alarming disproportionate burden of illness among certain population groups. The mission of the NIMHD is to lead scientific research aimed at the development of innovative diagnostics, treatments, and prevention strategies to improve minority health ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
75N91023R00034: National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2024
Release Date: 03-13-2023Open Date: 03-13-2023Due Date: 08-22-2023Close Date: 09-06-2023The National Cancer Institute is soliciting proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas: Development of therapeutic technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers. Development o ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-TR-22-032: Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (U43/U44- Clinical Trail Not Allowed)
Release Date: 09-19-2022Open Date: 10-21-2022 Due Dates: Multiple Close Date: 08-22-2023Section I. Funding Opportunity Description This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR)Phase I and Phase II (Fast track and Direct to phase II) grant applications. The funding opportunity will utilize a U43/U44 cooperative agreement to support small business concerns (SBCs) to propose a ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-TR-22-031: Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (UT1, UT2 Clinical Trail Not Allowed)
Release Date: 09-19-2022Open Date: 10-20-2022 Due Dates: Multiple Close Date: 08-22-2023This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR)Phase I and Phase II (no Direct to Phase II allowed) grant applications. The funding opportunity will utilize a UT1/UT2 cooperative agreement to support small business concerns (SBCs) to propose applications for the qualification of neuromuscu ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-CA-23-034: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
Release Date: 04-21-2023Open Date: 07-21-2023Due Date: 08-21-2023Close Date: 08-22-2023Purpose The Small Business Innovation Research (SBIR) Program is an important mechanism by which the National Institutes of Health (NIH) and other Federal agencies help bring innovative solutions to public health challenges. A major objective of the Federal SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of medic ...
SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-CA-23-035: Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)
Release Date: 04-21-2023Open Date: 07-21-2023Due Date: 08-21-2023Close Date: 08-22-2023Purpose Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), and National Institute on Drug Abuse (NIDA) intend to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small busin ...
SBIR/STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-ES-23-005: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
Release Date: 03-03-2023Open Date: 06-14-2023Due Date: 07-14-2023Close Date: 07-15-2023This SBIR Funding Opportunity Announcement (FOA) focuses on the development of e-Learning health and safety training products from a variety of delivery methods to assist both students and instructors in the training and education process. Note that all products must be directly related to the health and safety training of workers exposed to hazardous materials (HAZMAT). Workers that may be expose ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-TR-22-029: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)
Release Date: 07-13-2022Open Date: 07-18-2022 Due Dates: Multiple Close Date: 07-13-2023A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underlie multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molec ...
SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health